Dibenzepin

Dibenzepin

Systematic (IUPAC) name
10-(2-(dimethylamino)ethyl)-5-methyl-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	℞ (Prescription only)
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	25% (Oral)
Protein binding	80%
Metabolism	Hepatic
Biological half-life	5 hours
Excretion	Urine (80%), Feces (20%)
Identifiers
CAS Number	4498-32-2 Y
ATC code	N06AA08 (WHO)
PubChem	CID: 9419
ChemSpider	9048 Y
UNII	510SJZ1Y6L Y
KEGG	D07812 Y
ChEMBL	CHEMBL1442422 N
Chemical data
Formula	C18H21N3O
Molecular mass	295.379 g/mol
SMILES O=C2c1c(cccc1)N(c3c(N2CCN(C)C)cccc3)C
InChI InChI=1S/C18H21N3O/c1-19(2)12-13-21-17-11-7-6-10-16(17)20(3)15-9-5-4-8-14(15)18(21)22/h4-11H,12-13H2,1-3H3 Y Key:QPGGEKPRGVJKQB-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Dibenzepin (Noveril, Anslopax, Deprex, Ecatril, Neodit, Victoril) is a tricyclic antidepressant (TCA) used widely throughout Europe for the treatment of depression. It has similar efficacy and effects relative to other TCAs like imipramine but with fewer side effects. Dibenzepin acts as a norepinephrine reuptake inhibitor, potent antihistamine, and weak anticholinergic. It lacks any 5-HT₂ antagonistic properties.

Chronic pain

Like other tricyclic antidepressants, dibenzepin may have potential use in the treatment of chronic neuropathic pain.

Overdose

As tricyclic antidepressants have a relatively narrow therapeutic index, the likelihood of overdose (both accidental and intentional) is fairly high and should be considered carefully by the prescribing physician prior to patient use. Symptoms of overdose are similar to those of other tricyclic antidepressants, with cardiac toxicity (due to inhibition of sodium and calcium channels) generally occurring before the threshold for serotonin syndrome is reached. Due to this risk, tricyclic antidepressants are rarely selected as the first line treatment for depression.

See also

• Propizepine
• Nitroxazepine